HSP105 peptide-pulsed dendritic cell product

N/A

Report date: 2022/03/17 10:28:20

Base Information

Drug NameHSP105 peptide-pulsed dendritic cell product
Drug Alias NameHeat shock protein 105 peptide-pulsed dendritic cell vaccineCytotoxic T-lymphocyte stimulants-based cancer vaccineHSP105-derived cancer antigen peptide vaccineDendritic cell-stimulated vaccine
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionCytotoxic T lymphocytes stimulantsImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedinet
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of TokyoMedinet
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A